- Home
- NRIX vs SEZL Comparison
NRIX vs SEZL Comparison
Compare NRIX & SEZL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- SEZL
- Stock Information
- Founded
- NRIX 2009
- SEZL 2016
- Country
- NRIX United States
- SEZL United States
- Employees
- NRIX N/A
- SEZL N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- SEZL Diversified Financial Services
- Sector
- NRIX Health Care
- SEZL Finance
- Exchange
- NRIX Nasdaq
- SEZL Nasdaq
- Market Cap
- NRIX 1.4B
- SEZL 1.5B
- IPO Year
- NRIX 2020
- SEZL N/A
- Fundamental
- Price
- NRIX $19.60
- SEZL $229.76
- Analyst Decision
- NRIX Strong Buy
- SEZL Strong Buy
- Analyst Count
- NRIX 17
- SEZL 2
- Target Price
- NRIX $30.29
- SEZL $366.00
- AVG Volume (30 Days)
- NRIX 771.6K
- SEZL 144.2K
- Earning Date
- NRIX 02-13-2025
- SEZL 02-26-2025
- Dividend Yield
- NRIX N/A
- SEZL N/A
- EPS Growth
- NRIX N/A
- SEZL 1005.78
- EPS
- NRIX N/A
- SEZL 9.51
- Revenue
- NRIX $56,424,000.00
- SEZL $221,806,305.00
- Revenue This Year
- NRIX N/A
- SEZL $59.52
- Revenue Next Year
- NRIX $3.79
- SEZL $33.19
- P/E Ratio
- NRIX N/A
- SEZL $24.17
- Revenue Growth
- NRIX N/A
- SEZL 49.13
- 52 Week Low
- NRIX $7.65
- SEZL $30.41
- 52 Week High
- NRIX $29.56
- SEZL $477.53
- Technical
- Relative Strength Index (RSI)
- NRIX 48.04
- SEZL 39.76
- Support Level
- NRIX $18.75
- SEZL $210.23
- Resistance Level
- NRIX $20.50
- SEZL $324.77
- Average True Range (ATR)
- NRIX 1.08
- SEZL 26.88
- MACD
- NRIX 0.18
- SEZL 0.13
- Stochastic Oscillator
- NRIX 70.00
- SEZL 17.05
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
About SEZL Sezzle Inc.
Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase.